---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-038894"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:38:23.787820+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Axsome initiates Phase 3 ENGAGE trial of solriamfetol for binge eating disorder

## Summary
- Initiated ENGAGE Phase 3 trial of solriamfetol for binge eating disorder.
- Trial is randomized, double-blind, placebo-controlled with ~450 patients.
- Two doses (150 mg and 300 mg) vs placebo for 12 weeks; primary endpoint is change in binge eating episodes.
- First patient screened in March 2024.

## SEC filing metadata
- accession: 0000950170-24-038894
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017024038894/0000950170-24-038894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017024038894/axsm-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-038894
- JSON: https://secwatch.observer/filing/0000950170-24-038894.json
- Plain text: https://secwatch.observer/filing/0000950170-24-038894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.